PLoS ONE (Jan 2013)

Curcumin prevents replication of respiratory syncytial virus and the epithelial responses to it in human nasal epithelial cells.

  • Kazufumi Obata,
  • Takashi Kojima,
  • Tomoyuki Masaki,
  • Tamaki Okabayashi,
  • Shinichi Yokota,
  • Satoshi Hirakawa,
  • Kazuaki Nomura,
  • Akira Takasawa,
  • Masaki Murata,
  • Satoshi Tanaka,
  • Jun Fuchimoto,
  • Nobuhiro Fujii,
  • Hiroyuki Tsutsumi,
  • Tetsuo Himi,
  • Norimasa Sawada

DOI
https://doi.org/10.1371/journal.pone.0070225
Journal volume & issue
Vol. 8, no. 9
p. e70225

Abstract

Read online

The human nasal epithelium is the first line of defense during respiratory virus infection. Respiratory syncytial virus (RSV) is the major cause of bronchitis, asthma and severe lower respiratory tract disease in infants and young children. We previously reported in human nasal epithelial cells (HNECs), the replication and budding of RSV and the epithelial responses, including release of proinflammatory cytokines and enhancement of the tight junctions, are in part regulated via an NF-κB pathway. In this study, we investigated the effects of the NF-κB in HNECs infected with RSV. Curcumin prevented the replication and budding of RSV and the epithelial responses to it without cytotoxicity. Furthermore, the upregulation of the epithelial barrier function caused by infection with RSV was enhanced by curcumin. Curcumin also has wide pharmacokinetic effects as an inhibitor of NF-κB, eIF-2α dephosphorylation, proteasome and COX2. RSV-infected HNECs were treated with the eIF-2α dephosphorylation blocker salubrinal and the proteasome inhibitor MG132, and inhibitors of COX1 and COX2. Treatment with salubrinal, MG132 and COX2 inhibitor, like curcumin, prevented the replication of RSV and the epithelial responses, and treatment with salubrinal and MG132 enhanced the upregulation of tight junction molecules induced by infection with RSV. These results suggest that curcumin can prevent the replication of RSV and the epithelial responses to it without cytotoxicity and may act as therapy for severe lower respiratory tract disease in infants and young children caused by RSV infection.